Blurbs

Analysts Offer Insights on Healthcare Companies: Novavax (NVAX), Indaptus Therapeutics (INDP) and Zai Lab (ZLAB)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novavax (NVAXResearch Report), Indaptus Therapeutics (INDPResearch Report) and Zai Lab (ZLABResearch Report) with bullish sentiments.

Novavax (NVAX)

In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Novavax, with a price target of $126.00. The company’s shares closed last Monday at $57.25, close to its 52-week low of $34.88.

According to TipRanks.com, Mamtani ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -23.8% and a 27.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Lineage Cell Therapeutics, and Madrigal Pharmaceuticals.

Novavax has an analyst consensus of Moderate Buy, with a price target consensus of $103.17, representing an 80.2% upside. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $145.00 price target.

See the top stocks recommended by analysts >>

Indaptus Therapeutics (INDP)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Indaptus Therapeutics yesterday and set a price target of $11.00. The company’s shares closed last Monday at $3.31, close to its 52-week low of $1.89.

According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -38.8% and a 14.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group.

Indaptus Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $11.00.

Zai Lab (ZLAB)

Jefferies analyst Michael Yee maintained a Buy rating on Zai Lab yesterday and set a price target of $80.00. The company’s shares closed last Monday at $47.08.

According to TipRanks.com, Yee is a 1-star analyst with an average return of -1.2% and a 44.4% success rate. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Olema Pharmaceuticals, and Immunocore Holdings.

Zai Lab has an analyst consensus of Strong Buy, with a price target consensus of $80.00, a 69.9% upside from current levels. In a report released yesterday, Citigroup also maintained a Buy rating on the stock with a $199.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NVAX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos